Sarepta Therapeutics

YTD

ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

CEO

Douglas S. Ingram

CEODouglas S. Ingram

Employees

1,372

Employees1,372

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1980

Founded1980

Employees

1,372

Employees1,372

SRPT Key Statistics

Market cap

1.79B

Market cap1.79B

Price-Earnings ratio

-24.20

Price-Earnings ratio-24.20

Dividend yield

—

Dividend yield—

Average volume

6.00M

Average volume6.00M

High today

$18.39

High today$18.39

Low today

$17.57

Low today$17.57

Open price

$17.65

Open price$17.65

Volume

4.06M

Volume4.06M

52 Week high

$138.81

52 Week high$138.81

52 Week low

$10.42

52 Week low$10.42

SRPT News

Simply Wall St 4d

Why Sarepta Therapeutics Is Down After Halting Elevidys Use Amid Safety and Regulatory Concerns

Recently, Sarepta Therapeutics paused the use of its Elevidys gene therapy for non-ambulatory patients following reports of patient deaths, prompting a revision...

TipRanks 5d

Sarepta Therapeutics: Positioned for Growth Amidst Elevidys Uptake and Portfolio Diversification

Sarepta Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris from BMO Capital upgraded the rating...

TipRanks 5d

Sarepta upgraded to Outperform from Market Perform at BMO Capital

BMO Capital upgraded Sarepta (SRPT) to Outperform from Market Perform with an unchanged price target of $50. The firm appreciates the “credible concerns” around...

Analyst ratings

59%

of 27 ratings

Buy

22.2%

Hold

59.3%

Sell

18.5%

More SRPT News

Simply Wall St 6d

Sarepta Therapeutics: Assessing Valuation After Elevidys Safety Halt and Lowered 2025 Revenue Guidance

Sarepta Therapeutics (SRPT) has landed back in the spotlight after safety concerns tied to its Elevidys gene therapy prompted a halt for non-ambulatory patients...

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.